AstraZeneca breast cancer drug fails trial but Citi keeps 'buy' rating

finance.yahoo.com · 2026-09-14

AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental breast cancer drug camizestrant has failed a late-stage trial, though analysts at Citi say the setback does little to dent the company's prospects. Citi kept its 'buy' rating and £178 target price on the FTSE 100 pharmaceuticals group,...

TickrTrends take: AstraZeneca faced a setback with a failed clinical trial for a breast cancer drug, which typically creates downward pressure on biopharmaceutical stocks during the development phase. Despite this development, analyst support remains intact with Citi maintaining a buy rating, suggesting confidence in the company's broader pipeline and financial positioning. Given TickrTrends' current undervalued assessment, investors focused on valuation metrics should monitor whether this trial failure impacts future earnings guidance or pipeline probability assumptions in upcoming financial disclosures.

Read the full story at finance.yahoo.com →